- Chronic leukemia
- Acute Leukemia
- Others
Leukemia Treatment Market size was valued at USD 14.09 billion in 2023 and is expected to reach USD 26.08 billion by 2030, at a CAGR of 7.9% during the forecast period 2024-2030. Abnormal white blood cells beginning in the bone marrow of blood forming tissues results in a group of cancers collectively called as Leukemia. Leukemia is a cancer of blood-forming tissues in the body. Treatment of leukemia is done by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy, biological therapy, targeted therapy, stem cell transplant. The drugs that are available in the market include the following Gleevec, Bosulif, Sprycel, Iclusig etc. Bosutinib, omapro, quizartinib, graspa, and marquibo among others are the pipeline drugs under clinical trials yet to be launched with a promising potential to treat leukemia with minimal side effects.
Based on the epidemiological factors, leukemia is forecasted to be more predominant in whites when compared to people of other racial or ethnic groups due to high incidence and mortality rates. Furthermore, exposure to radiation with genetic and environmental factors play a prominent role in increasing the prevalence of leukemia. Generally, men are more likely to develop leukemia than women. The risk of leukemia is majorly associated with age. The occurrence of leukemia is high in men and women aging over 66 years. Adults, both men and women normally aged in between 75 to 84 are more prevalent to the different types of leukemia such as chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The prevalent rate of acute lymphocytic leukemia is high among 1 to 4 year old children and it is nearly eight times more than the young adults aging 20 and 24.
Leukemia Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7.9%
Largest Market
North-America
Fastest Growing Market
Asia-Pacific
Leukemia Treatment Market Dynamics
The global leukemia treatment market is majorly driven by the increasing prevalance of the disease across the globe. Healthcare awareness among the people and rising research & development activities resulting in recent advancements of technology and therapeutics. The growth rate of global leukemia treatment market also depends on the pipeline drugs which are major growth drivers for global leukemia therapeutics market in near future. The factors restraining the growth of the market include the high price of combination therapies and lack of access in developing and underdeveloped countries.
North-America got significant share
Leukemia Treatment Market Regional Analysis
Geographically, global leukemia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. America's leukemia treatment market is growth driven by increase in the prevalence of leukemia. According to NIH the number of new cases of leukemia was 13.7 per 100,000 men and women per year. The number of deaths was 6.8 per 100,000 men and women per year. Almost 1.5 percent of men and women will be diagnosed with leukemia at some point during their lifetime, based on 2012-2014 data. In the year of 2014, there were an estimated 387,728 people living with leukemia in the United States. The government and non-government organizations programs like patient assistance are also expected to fuel the market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The leukemia treatment market report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
- The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startups details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Leukemia Treatment Market Segmentation
By Type
By Therapy type
- Chemotherapy
- Biological Therapy
- Radiation therapy
- Targeted therapy
- Other
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Afica
Frequently Asked Questions
The Leukemia Treatment Market size was valued at USD 14.09 billion in 2022
The Leukemia Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Leukemia Treatment Market
| 1.Executive Summary |
| 2.Global Leukemia Treatment Market Introduction |
| 2.1.Global Leukemia Treatment Market - Taxonomy |
| 2.2.Global Leukemia Treatment Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Therapy type |
| 2.2.3.Region |
| 3.Global Leukemia Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Leukemia Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Leukemia Treatment Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Chronic leukemia |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Acute Leukemia |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Leukemia Treatment Market By Therapy type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Chemotherapy |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Biological Therapy |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Radiation therapy |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Targeted therapy |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Other |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Leukemia Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Leukemia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Chronic leukemia |
| 8.1.2.Acute Leukemia |
| 8.1.3.Others |
| 8.2. Therapy type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Chemotherapy |
| 8.2.2.Biological Therapy |
| 8.2.3.Radiation therapy |
| 8.2.4.Targeted therapy |
| 8.2.5.Other |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Leukemia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chronic leukemia |
| 9.1.2.Acute Leukemia |
| 9.1.3.Others |
| 9.2. Therapy type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Chemotherapy |
| 9.2.2.Biological Therapy |
| 9.2.3.Radiation therapy |
| 9.2.4.Targeted therapy |
| 9.2.5.Other |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Leukemia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chronic leukemia |
| 10.1.2.Acute Leukemia |
| 10.1.3.Others |
| 10.2. Therapy type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Chemotherapy |
| 10.2.2.Biological Therapy |
| 10.2.3.Radiation therapy |
| 10.2.4.Targeted therapy |
| 10.2.5.Other |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Leukemia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chronic leukemia |
| 11.1.2.Acute Leukemia |
| 11.1.3.Others |
| 11.2. Therapy type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Chemotherapy |
| 11.2.2.Biological Therapy |
| 11.2.3.Radiation therapy |
| 11.2.4.Targeted therapy |
| 11.2.5.Other |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Leukemia Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chronic leukemia |
| 12.1.2.Acute Leukemia |
| 12.1.3.Others |
| 12.2. Therapy type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Chemotherapy |
| 12.2.2.Biological Therapy |
| 12.2.3.Radiation therapy |
| 12.2.4.Targeted therapy |
| 12.2.5.Other |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.F. Hoffmann-La Roche Ltd. |
| 13.2.2.Amgen |
| 13.2.3.Bristol-Myers Squibb |
| 13.2.4.Novartis International AG. |
| 13.2.5.Pfizer |
| 13.2.6.Teva Pharmaceuticals |
| 13.2.7.GlaxoSmithKline plc. |
| 13.2.8.Genzyme Corporation |
| 13.2.9.AbbVie Inc. |
| 13.2.10.ARIAD Pharmaceuticals, Inc |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- F. Hoffmann-La Roche Ltd.
- Amgen
- Bristol-Myers Squibb
- Novartis International AG.
- Pfizer
- Teva Pharmaceuticals
- GlaxoSmithKline plc.
- Genzyme Corporation
- AbbVie Inc.
- ARIAD Pharmaceuticals, Inc.